Abstract
A simple method based on hydrolysis of 2,3-dicyanopyrazinium salts has been used for the synthesis of the corresponding 5-(hetero)aryl-3-cyano-1-ethyl-2(1H)-pyrazinones. Also, the series of novel 1-ethyl-5-(hetero)aryl-1,6-dihydropyrazine-2,3-dicarbonitriles have been obtained through reduction of the same pyrazinium salts with triethylsilane. The obtained compounds proved to be active in micromolar concentrations in vitro against Mycobacterium tuberculosis H37Rv, Mycobacterium avium, Mycobacterium terrae, as well as against rifampicin and isoniazid-resistance strains of Mycobacterium tuberculosis. The data for acute in vivo toxicity in mice have been obtained for these compounds which appear to be promising antitubercular agents.
Keywords: Pyrazine, 2(1H)-Pyrazinone, antituberculosis activity, tuberculosis, mycobacterium avium, mycobacterium terrae.
Anti-Infective Agents
Title:Synthesis and Antitubercular Evaluation on Novel 1-Ethyl-5-(hetero)aryl- 1,6-dihydropyrazine-2,3-dicarbonitriles and 3-Cyano-1-ethyl-5-(hetero) aryl-2(1H)-pyrazinones
Volume: 14 Issue: 2
Author(s): Marionella A. Kravchenko, Egor V. Verbitskiy, Sergey N. Skornyakov, Pavel A. Slepukhin, Gennagy L. Rusinov, Oleg N. Chupakhin and Valery N. Charushin
Affiliation:
Keywords: Pyrazine, 2(1H)-Pyrazinone, antituberculosis activity, tuberculosis, mycobacterium avium, mycobacterium terrae.
Abstract: A simple method based on hydrolysis of 2,3-dicyanopyrazinium salts has been used for the synthesis of the corresponding 5-(hetero)aryl-3-cyano-1-ethyl-2(1H)-pyrazinones. Also, the series of novel 1-ethyl-5-(hetero)aryl-1,6-dihydropyrazine-2,3-dicarbonitriles have been obtained through reduction of the same pyrazinium salts with triethylsilane. The obtained compounds proved to be active in micromolar concentrations in vitro against Mycobacterium tuberculosis H37Rv, Mycobacterium avium, Mycobacterium terrae, as well as against rifampicin and isoniazid-resistance strains of Mycobacterium tuberculosis. The data for acute in vivo toxicity in mice have been obtained for these compounds which appear to be promising antitubercular agents.
Export Options
About this article
Cite this article as:
Kravchenko A. Marionella, Verbitskiy V. Egor, Skornyakov N. Sergey, Slepukhin A. Pavel, Rusinov L. Gennagy, Chupakhin N. Oleg and Charushin N. Valery, Synthesis and Antitubercular Evaluation on Novel 1-Ethyl-5-(hetero)aryl- 1,6-dihydropyrazine-2,3-dicarbonitriles and 3-Cyano-1-ethyl-5-(hetero) aryl-2(1H)-pyrazinones, Anti-Infective Agents 2016; 14 (2) . https://dx.doi.org/10.2174/2211352514666160728160218
DOI https://dx.doi.org/10.2174/2211352514666160728160218 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
Call for Papers in Thematic Issues
An Overview of Drugs for Multiple Targets and Variants of SARS-CoV-2 Through Artificial Intelligence, Machine Learning, Deep Learning, and Experimental Analysis
The emergence and rapid evolution of SARS-CoV-2 variants have posed significant challenges in the ongoing fight against the COVID-19 pandemic. The development of effective treatments for multiple viral targets and variants demands innovative approaches, including artificial intelligence (AI), machine learning (ML), and deep learning (DL) techniques. This special issue aims ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Metabolic Syndrome and HIV Infection
Current Pharmaceutical Design Distribution and Characteristics of Intrathoracic Lymphadenopathy in TB/HIV Co-Infection
Infectious Disorders - Drug Targets Interstitial Lung Disease Associated with Collagen Vascular Disease
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Editorial (Thematic Issue: Polypharmacology in Drug Discovery)
Current Pharmaceutical Design Therapeutic Approaches Blocking Glycan Synthesis as Targeting Strategy for Malaria
Current Clinical Pharmacology Integration of Biological Data with Semantic Networks
Current Bioinformatics The Aromatic Stacking Interactions Between Proteins and their Macromolecular Ligands
Current Protein & Peptide Science Potential Triazole-based Molecules for the Treatment of Neglected Diseases
Current Medicinal Chemistry Potential Application of Network Descriptions for Understanding Conformational Changes and Protonation States of ABC Transporters
Current Pharmaceutical Design Genomic Instability in Cancer: Molecular Mechanisms and Therapeutic Potentials
Current Pharmaceutical Design Prevention and Therapeutic Strategies of Thromboembolic Events in Patients with Inflammatory Bowel Diseases: A Report of Three Cases
Current Drug Targets Vitamin D Metabolism Genes in Asthma and Atopy
Mini-Reviews in Medicinal Chemistry Present and Future Treatment of Mycobacteria
Anti-Infective Agents in Medicinal Chemistry Characterizing the Binding of Angiotensin Converting Enzyme I Inhibitory Peptide to Human Hemoglobin: Influence of Electromagnetic Fields
Protein & Peptide Letters A Review on Extraction, Synthesis and Anticancer Activity of Betulinic Acid
Current Bioactive Compounds Exosomes: Critical Mediators of Tumour Microenvironment Reprogramming
Current Medicinal Chemistry PEGylated Dendritic Architecture for Development of a Prolonged Drug Delivery System for an Antitubercular Drug
Current Drug Delivery Advances and Application of DNA-functionalized Nanoparticles
Current Medicinal Chemistry Other Activities
Current Bioactive Compounds Clostridium difficile Infection in Children with Inflammatory Bowel Disease: Current Evidence
Current Pharmaceutical Design